Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
HealthDay News — Patient enrollment in cancer treatment trials is 7.1%, higher than historical estimates, according to a study published online April 2 in the Journal of Clinical Oncology.
Joseph M. Unger, PhD, from the Fred Hutchinson Cancer Center in Seattle, and colleagues provided contemporary estimates of clinical trial participation among adults with cancer. The analysis included a national sample of accreditation information submitted by the 1200 Commission on Cancer programs, which represent 70% or greater of all US cancer cases.
The researchers found that the overall estimated patient participation rate in cancer treatment trials was 7.1%. Participation was also seen in a wide variety of other studies, including biorepository (12.9%), registry (7.3%), genetic (3.6%), quality-of-life (2.8%), diagnostic (2.5%), and economic (2.4%) studies. For treatment trials, enrollment occurred in National Cancer Institute-designated comprehensive cancer centers (21.6%), academic (non–National Cancer Institute-designated) comprehensive cancer programs (5.4%), integrated network cancer programs (5.7%), and community programs (4.1%). Just over 1 in 5 patients participated in 1 or more cancer clinical research studies (21.9%).
“Contributions of adult patients with cancer to clinical research is more common than previously understood,” the authors write.
